Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Medicines Company (NasdaqNM:MDCO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
One Cambridge Center
Cambridge, MA 02142
Phone: (617) 225-9099
Fax: (617) 225-2329
Email: investor.relations@themedco.com
Employees (last reported count): 74
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 75%
·Over the last 6 months:
 · 2 insider buys; 11.0K shares
 · 2 insider sells; 80.0K shares
  (0.3% of insider shares)
·Institutional: 51% (206% of float)
(99 institutions)
·Net Inst. Buying: 2.46M shares (+12.18%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
The Medicines Company acquires, develops and commercializes biopharmaceutical products that are in late stages of development or have been approved for marketing. In December 2000, the Company received marketing approval from the United States Food and Drug Administration (FDA) for Angiomax, its lead product, for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty. The Company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition that occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow. To date, clinical investigators have administered Angiomax to approximately 12,600 patients in clinical trials in the treatment and prevention of blood clots in a wide range of hospital applications. The Company believes that Angiomax will become the leading replacement for heparin in hospital care.
More from Market Guide: Expanded Business Description

Financial Summary
The Medicines Company acquires, develops and commercializes biopharmaceutical products in the late stages of development. For the six months ended 6/30/01, revenues totaled $4 million, up from $0. Net loss applicable to Common decreased 49% to $35 million. Revenues reflect the launch of the Company's lead product, Angiomax. Lower loss reflects the absence of a $19.4 million interest expense and a $28.7 million preferred stock dividend.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Clive Meanwell, M.D., Ph.D., 43
Pres, CEO, Director
$335K--  
Peyton Marshall, Ph.D., 45
Sr. VP, CFO
270K--  
Glenn Sblendorio, 44
Sr. VP
--  --  
David Stack, 49
Sr. VP
--  --  
John Nystrom, Ph.D., 55
VP, CTO
215K$348K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MDCOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-Mar-2001
$8.75 
Recent Price$11.50 
52-Week High
on 29-Sep-2000
$35.375
Daily Volume (3-month avg)313.0K
Daily Volume (10-day avg)567.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-53.3%
52-Week Change
relative to S&P500
-37.3%
Share-Related Items
Market Capitalization$397.2M
Shares Outstanding34.5M
Float8.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.28 
Earnings (ttm)-$2.54 
Earnings (mrq)-$0.49 
Sales (ttm)$0.14 
Cash (mrq)$2.59 
Valuation Ratios
Price/Book (mrq)5.04 
Price/EarningsN/A 
Price/Sales (ttm)80.18 
Income Statements
Sales (ttm)$3.91M
EBITDA (ttm)-$64.6M
Income available to common (ttm)-$68.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-92.03%
Return on Equity (ttm)-200.73%
Financial Strength
Current Ratio (mrq)4.72 
Debt/Equity (mrq)0 
Total Cash (mrq)$89.6M
Short Interest
As of 8-Aug-2001
Shares Short1.06M
Percent of Float12.3%
Shares Short
(Prior Month)
680.0K
Short Ratio4.74 
Daily Volume224.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.